Arcus Biosciences (RCUS) Accumulated Expenses (2017 - 2023)

Arcus Biosciences' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $15.0 million for Q2 2023.

• In Q2 2023, Accumulated Expenses rose 15.9% year-over-year to $15.0 million; the TTM figure through Jun 2023 stood at $15.0 million (up 15.9% YoY), while the FY2022 annual figure was $25.0 million, up 47.06% from the prior year.
• Accumulated Expenses was $15.0 million for Q2 2023 at Arcus Biosciences, up from $12.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $25.0 million in Q4 2022 to a low of $2.0 million in Q1 2019.
• Historically, Accumulated Expenses has averaged $10.9 million across 5 years, with a median of $10.7 million in 2019.
• The sharpest annual moves came in 2019 and 2020: Accumulated Expenses soared 717.67% in 2019, then tumbled 74.41% in 2020.
• A 5-year view of Accumulated Expenses shows it stood at $5.0 million in 2019, then surged by 92.79% to $9.5 million in 2020, then jumped by 78.14% to $17.0 million in 2021, then jumped by 47.06% to $25.0 million in 2022, then slumped by 40.0% to $15.0 million in 2023.
• The last three Accumulated Expenses figures came in at $15.0 million (Q2 2023), $12.0 million (Q1 2023), and $25.0 million (Q4 2022), per Business Quant data.